A Study of Remternetug in Early Alzheimer’s Disease
Research type
Research Study
Full title
A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline
IRAS ID
1010927
Contact name
Evgenii Karpov
Contact email
Sponsor organisation
Eli Lilly and Co.
Clinicaltrials.gov Identifier
Research summary
Alzheimer's disease (AD) is the most common type of dementia in the UK. The exact cause of AD is not yet fully understood, although a number of factors are thought to increase your risk of developing the condition including increasing age and family history. AD affects multiple brain functions and is thought to be caused by the abnormal build-up of proteins in and around brain cells. One of the proteins involved is called amyloid, deposits of which form plaques around brain cells. It has been demonstrated that interventions that clear these plaques slow the progression of AD. Remternetug is an antibody that targets and removes deposited amyloid plaques. In study J1G-MC-LAKI, participants with early AD will receive either remternetug or placebo via subcutaneous administration. People with early AD have an abnormal protein in their brain but may or may not have problems with their memory or thinking. Study LAKI will assess whether treatment with remternetug can slow the progression of the disease in patients with early AD. There is an open label extension period in this trial whereby eligible participants who previously received placebo may access remternetug.
Patient participation is expected to last up to 5 years. Approximately 1200 participants will be enrolled in the study globally, including approximately 70 participants from the UK.REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
24/EM/0243
Date of REC Opinion
6 Dec 2024
REC opinion
Further Information Favourable Opinion